Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. The company operates through two segments, Biopharmaceuticals and Exemplar. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristics of immune cells; Sleeping Beauty, a non-viral transposon/transposase system; AttSite recombinases, which breaks and rejoins DNA at specific sequences; AdenoVerse technology platform, a library of engineered adenovector serotypes; and Lactococcus lactis, a food-grade bacterium. Additionally, it provides RheoSwitch Therapeutic System, an inducible gene switch system that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression; kill switches to selectively eliminate cell therapies in vivo; tissue-specific promoters; UltraCAR-T platform for the treatment of cancer; AdenoVerse Immunotherapy, a library of proprietary adenovectors for the gene delivery; and ActoBiotics platform, genetically modified bacteria that deliver proteins and peptides at mucosal sites. Precigen, Inc. has collaboration and license agreements with Alaunos Therapeutics, Inc.; Intrexon Energy Partners, LLC; and Intrexon Energy Partners II, LLC. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.
-0.37EPS Dil.
-3.82P/E
358.96MMarket Cap
Working Capital
FRC
•
in mil. unless spec.
Mar'23
Jun'23
Sep'23
Total Current Assets
138
106
93
Cash, Cash Equivalents & STI
104
88
74
Accounts Receivable, Net
2
1
1
Inventories
- -
- -
- -
Total Current Liabilities
47
31
33
Payables & Accruals
27
25
25
ST Debt
15
1
1
Deferred Revenue
0
0
1
- -
- -
- -
- -
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
- -
- -
- -
- -
1.41
2.52
0.58
0.73
1.56
1.62
1.92
1.24
0.54
0.62
0.53
0.13
0.03
Revenue per ShareRevenue per Share
- -
- -
- -
- -
-17.50
-18.77
-1.40
-0.83
-0.76
-1.58
-0.98
-3.93
-1.93
-1.02
-0.47
0.14
-0.37
Basic EPS, GAAPBasic EPS, GAAP
- -
- -
- -
- -
-16.73
-12.47
-1.35
-0.26
0.21
-0.74
-1.26
-1.28
-1.04
-0.51
-0.32
-0.35
-0.29
Free Cash Flow per Basic ShareFree Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per ShareDividend per Share
- -
- -
- -
- -
-39.06
-58.10
-3.88
-4.56
-4.65
-6.14
-6.94
-8.31
-10.12
-9.72
-9.27
-8.98
-7.53
Book Value per ShareBook Value per Share
- -
- -
- -
- -
-98.05
-136.92
3.35
2.41
2.50
1.57
1.31
0.62
-0.37
-0.28
0.00
0.22
0.27
Tangible Book Value per ShareTangible Book Value per Share